A5077332893- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Advanced biosensing and bioanalysis techniques
- Chemokine receptors and signaling
- Glycosylation and Glycoproteins Research
- Immune cells in cancer
- Histone Deacetylase Inhibitors Research
- Global Cancer Incidence and Screening
- Protein Degradation and Inhibitors
- T-cell and B-cell Immunology
- RNA Interference and Gene Delivery
Washington University in St. Louis
2021-2024
National Cancer Institute
2023
Center for Cancer Research
2023
Abstract Rational design of chimeric antigen receptor T (CAR-T) cells based on the recognition antigenic epitopes capable evoking most potent CAR activation is an important objective in optimizing immune therapy. In solid tumors, B7-H3 transmembrane protein emerging target that harbours two distinct epitope motifs, IgC and IgV, its ectodomain. Here, we generate dromedary camel nanobodies targeting demonstrate CAR-T cells, recognizing but not IgV domain, had antitumour activity against large...
Multiple myeloma (MM) is the cancer of plasma cells within bone marrow and remains incurable. Tumor-associated macrophages (TAMs) tumor microenvironment often display a pro-tumor phenotype correlate with proliferation, survival, therapy resistance. IL-10 key immunosuppressive cytokine that leads to recruitment development TAMs. In this study, we investigated role in MM TAM as well therapeutic application IL-10/IL-10R/STAT3 signaling inhibition. We demonstrated overexpressed BM mediates...
Acute myeloid leukemia (AML) is the most common type of and has a 5-year survival rate 25%. The standard-of-care for AML not changed in past few decades. Promising immunotherapy options are being developed treatment AML; yet, these regimens require highly laborious sophisticated techniques. We create nanoTCEs using liposomes conjugated to monoclonal antibodies enable specific binding. also recreate bone marrow niche our 3D culture system use immunocompromised mice human T cells with...
Abstract Background and significance Chimeric antigen receptor (CAR)-T cell therapy shows promising potency for treating patients with hematological malignancies. However, follow-up data indicate that only 30% to 50% of these experience long-term disease control. In solid tumors, the B7-H3 transmembrane protein is an emerging target harbors in its ectodomain two distinct epitope motifs - IgC IgV. Here, we developed nanobody-based CAR-T strategy targeting investigated anti-tumor efficacy...
Acute myeloid leukemia (AML) is the most common type of leukemia. Emerging immunotherapies such as chimeric antigen receptor T (CAR-T) cells and cell engagers (TCEs), have potential to enhance recognition response against cancers, but come with serious limitations short half-life, complex production, high cost, inability customize for another antigen. To overcome these limitations, we previously developed a nanoparticle-based (nanoTCEs) technology that has longer half-life (60h vs 2h TCEs),...
e18534 Background: Mammography screening significantly reduces breast-cancer related mortality; however, many women fail to undergo as recommended by national guidelines. No-shows are responsible for a significant proportion of delayed or missed cancer exams. Further, no-shows disproportionately affect underserved and minority populations. We previously identified high no-show rate mammograms among patients seeking care our institution. African American (AA) were almost three times more...
<title>Abstract</title> Multiple myeloma (MM) is the cancer of plasma cells within bone marrow (BM) and remains incurable. Tumor-associated macrophages (TAMs) tumor microenvironment often display a pro-tumor phenotype correlate with proliferation, survival, therapy resistance. Thus, TAMs have become an emerging target interest. IL-10 key immunosuppressive cytokine that leads to recruitment development TAMs. In this study, we investigated role in MM TAM as well therapeutic application...